Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. | Zendy

Pierre Zoldhelyi | Zendy; Mark Webster | Zendy; Valentı́n Fuster | Zendy; Diane E. Grill | Zendy; D Gáspár | Zendy; Susan J. Edwards | Zendy; Catherine F. Cabot | Zendy; James H. Chesebro | Zendy

Open Access

Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.

Author(s) -

Pierre Zoldhelyi,

Mark Webster,

Valentı́n Fuster,

Diane E. Grill,

D Gáspár,

Susan J. Edwards,

Catherine F. Cabot,

James H. Chesebro

Publication year - 1993

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.88.5.2015

Subject(s) - medicine , hirudin , partial thromboplastin time , antithrombin , antithrombotic , coronary artery disease , anticoagulant , thrombolysis , coagulation , anesthesia , cardiology , gastroenterology , thrombin , heparin , platelet , myocardial infarction

Because the specific antithrombin hirudin prevents platelet-rich arterial thrombus and accelerates thrombolysis in a variety of animal models, it has promise as antithrombotic therapy. We therefore studied the half-life, effect on anticoagulant parameters, and safety of hirudin in patients with coronary artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research